Management of Post-cholecystectomy Bile Leaks: Predictors for persistent leak after initial ERCP



Song, Mingjun²; Mohammad Nader, Setarah¹; Fogel, Evan L²; Gromski, Mark A²; Watkins, James L²; Easler, Jeffrey J²; Gutta, Aditya²; Bick, Benjamin Lo²; Tong Yan³ ¹Internal Medicine, Indiana University School Of Medicine; ²Division Of Gastroenterology, Indiana University School of Medicine

Introduction

Endoscopic retrograde cholangiopancreatography (ERCP) is a 1st-line treatment for post-cholecystectomy bile leaks (PCBL). Despite appropriate initial ERCP interventions that optimize transpapillary bile flow, PCBL can persist. We aim to evaluate baseline clinical factors associated with persistent PCBL after initial ERCP.

Methods and Materials

We created a retrospective database of patients with PCBL referred for ERCP at Indiana University Health (IUH) University Hospital. Data collected included endoscopic reports, fluoroscopic imaging, patient demographics, type of PCBL, ERCP timing and interventions, technical success, and treatment outcomes.

A high-grade bile leak (HG-BL) was defined as visualization of contrast extravasation from the bile duct before filling of intrahepatic biliary branches with contrast (**Image 1**) The PCBL was deemed to be persistent if > 1 interventional ERCP was required for the leak to resolve on cholangiogram.





Image 1. Example of a high-grade bile leak from common bile duct (Strasberg class D) after cholecystectomy.

Our study suggests that a HG-BL in a male patient may justify more aggressive ERCP interventions or more prolonged stent indwell time. As a tertiary referral hospital, we had a significant referral bias in our cohort, which could have acted as a confounder causing statistical significance for lower initial ERCP success rates at outside medical facilities. The relatively high volume of ERCP cases at our center may also have contributed to better ERCP outcomes.





From 2011 to 2021, 369 cases of PCBL were referred for ERCP. After excluding cases with transected bile ducts (n=21) and patients lost to follow up (n=15), 333 cases were included in data analysis (**Image 2**).


Results

21 patients received their initial ERCP at an outside hospital. All patients received biliary sphincterotomy with stenting unless there was coagulopathy or Roux-en-Y gastric bypass (n=12).

Univariate logistic regression analysis identified male gender, steroids use at time of ERCP, presence of duodenal stricture, a HG-BL, Strasberg class D PCBL, presence of biloma, presence of abdominal drain, presence of biliary stricture, and initial ERCP performed at outside hospital to be significant variables for persistent PCBL (Table 1).

On multivariate analysis, presence of a HG-BL (OR 7.08, CI 1.96 – 25.58, p = 0.003) and initial ERCP performed at an outside facility (OR 29.14, CI 3.35 – 253.63, p=0.002) remained significantly associated with persistent PCBL. Being a female gender (OR 0.30, CI 0.11 – 0.85, P = 0.022) remained significant for higher odds of PCBL resolution after initial ERCP.





Discussion






Table 1. Univariate analysis of clinical variables for persistent PCBL after initial ERCP treatment.

Variables **Patient Characteristics**

> Female Age 55 years old or more Median BMI (IQR) On diabetic treatment **On steroids**

Major papilla within duodenal dive **Duodenal stricture/stenos**

Location and timing of ERCP Proced ERCP performed > 3 days **Initial ERCP performed at out** facility

Bile leak characteristics Strasberg Class A bile leaks Strasberg Class D bile leak Bile leak from cystic duct* **Bile leak from duct of Lusch Bile leak from common bil** duct/common hepatic duc High-grade bile leak **Concomitant biloma prese** Percutaneous abdominal drain p **Presence of biliary stones Presence of biliary stricture ERCP** interventions Biliary sphincterotomy perform Biliary sphincterotomy alone

> Biliary stenting alone Bridging biliary stents Multiple biliary plastic stents Self-expandable metal sten

INDIANA UNIVERSITY SCHOOL OF MEDICINE



Initial ERCP failure	OR (95% CI)	P value
25/204 (12.25%)	0.49 (0.27 – 0.86)	0.013
34/175 (19.43%)	1.60 (0.90-2.86)	0.112
32.0 (26.0, 36.0)	1.00 (0.98 – 1.03)	0.874
13/58 (22.41%)	1.81 (0.93 – 3.53)	0.083
4/6 (66.67%)	10.18 (1.82 – 57.00)	0.008
11/57 (19.30%)	1.46 (0.73 – 2.93)	0.282
5/10 (50.00%)	5.17 (1.45 – 18.48)	0.011
48/273 (17.58%)	1.00 (0.47 – 2.12)	0.994
17/21 (80.95%)	30.94 (9.96 - 96.06)	<0.001
44/302 (14.57%)	0.26 (0.12 – 0.54)	<0.001
10/31 (32.26%)	2.70 (1.19 – 6.12)	0.018
34/192 (17.71%)	1.25 (0.70 – 2.24)	0.446
4/104 (3.85%)	0.21 (0.09 – 0.50)	<0.001
7/25 (28.00%)	2.66 (1.13 – 6.27)	0.025
25/63 (39.68%)	4.80 (2.58 – 8.95)	< 0.001
27/115 (23.48%)	2.06 (1.13 – 3.76)	0.018
42/204 (20.59%)	2.02 (1.07 – 3.82)	0.030
5/67 (7.46%)	0.34 (0.13 – 0.88)	0.026
7/21 (33.33%)	2.63 (1.01 – 6.84)	0.048
56/325 (17.23%)	1.04 (0.22 – 4.88)	0.960
2/6 (33.33%)	2.46 (0.44 – 13.73)	0.306
2/12 (16.67%)	0.96 (0.21 – 4.51)	0.960
20/134 (14.93%)	0.78 (0.43 – 1.43)	0.426
6/55 (10.91%)	0.55 (0.22 – 1.36)	0.198
2/11 (18.18%)	1.09 (0.23 – 5.21)	0.910
	$\begin{array}{c} 25/204 (12.25\%) \\ 34/175 (19.43\%) \\ 32.0 (26.0, 36.0) \\ 13/58 (22.41\%) \\ 4/6 (66.67\%) \\ 11/57 (19.30\%) \\ 5/10 (50.00\%) \\ 5/10 (50.00\%) \\ 5/10 (50.00\%) \\ 17/21 (80.95\%) \\ 17/21 (80.95\%) \\ 17/21 (80.95\%) \\ 10/31 (32.26\%) \\ 34/192 (17.71\%) \\ 4/104 (3.85\%) \\ 7/25 (28.00\%) \\ 7/25 (28.00\%) \\ 25/63 (39.68\%) \\ 27/115 (23.48\%) \\ 42/204 (20.59\%) \\ 5/67 (7.46\%) \\ 7/21 (33.33\%) \\ 2/6 (33.33\%) \\ 2/12 (16.67\%) \\ 20/134 (14.93\%) \\ 6/55 (10.91\%) \\ \end{array}$	$\begin{array}{c} 25/204 \ (12.25\%) & 0.49 \ (0.27-0.86) \\ 34/175 \ (19.43\%) & 1.60 \ (0.90-2.86) \\ 32.0 \ (26.0, 36.0) & 1.00 \ (0.98-1.03) \\ 13/58 \ (22.41\%) & 1.81 \ (0.93-3.53) \\ 4/6 \ (66.67\%) & 10.18 \ (1.82-57.00) \\ 11/57 \ (19.30\%) & 1.46 \ (0.73-2.93) \\ 5/10 \ (50.00\%) & 5.17 \ (1.45-18.48) \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$